Blog · Ocular surface

IPL for dry eyes: the complete guide

Published June 25, 2026

Do your eyes sting or burn, feel gritty or tired by the end of the day, and artificial tears are no longer enough? In the vast majority of cases, dry eye comes from meibomian gland dysfunction — the glands in your eyelids that produce the oily layer protecting your tears. IPL (intense pulsed light) is one of the tools I use at the OPHTALIFE practice to address this underlying cause.

In this guide, I explain why your eyes are dry, what IPL really is and how it works, the 4-session protocol, who it is suitable for — and who it is not — what the studies say, and how coverage works. The goal: to help you come to your consultation understanding what is at stake.

Dry eyes Meibomian glands MGD 4 sessions In-office
C.stim ophthalmic IPL device used at the OPHTALIFE practice to treat dry eye disease and meibomian gland dysfunction
Understanding

Why your eyes are dry

Before discussing treatment, we need to understand where the dryness comes from. Most often, the problem is not a lack of tears, but their poor quality.

The tear film: a delicate balance

Your tears are not just a drop of water: they form a film made up of three layers. A lipid (oily) layer, produced by the meibomian glands located within the eyelids, which limits evaporation. An aqueous layer, produced by the lacrimal gland. And a mucin layer, which helps the whole film adhere to the cornea.

A dysfunction in just one of these layers is enough to cause dryness. And in a large share of dry eye cases, it is the lipid layer that is at fault — in other words, meibomian glands that no longer work properly [6].

Meibomian gland dysfunction (MGD), simply explained

Over time — with age, screens, and certain skin inflammations such as rosacea — the secretions of the meibomian glands become thicker and eventually clog the glands. The oily layer thins out and tears evaporate too quickly: this is known as evaporative dry eye.

Meibomian gland dysfunction is often associated with chronic blepharitis, sometimes sustained by microscopic mites (Demodex) or rosacea. It is a chronic, fluctuating disease: the aim of treatment is to keep it under control over the long term, not to hope for a permanent cure. To learn more, see my page on dry eye disease.

The technology

What is IPL?

IPL (Intense Pulsed Light) is a non-invasive technology that originated in dermatology and is now used in ophthalmology to treat meibomian gland dysfunction.

One light, many wavelengths

IPL emits polychromatic light covering a broad range of wavelengths (approximately 500 to 1,200 nanometers). Unlike a laser, which emits a single wavelength, this diversity allows it to act on several targets at once, in the skin of the eyelids and the surrounding area.

The light is delivered in very short pulses, with controlled intensity and duration. It penetrates a few millimeters into the skin and generates localized heat there, with no incision, no abrasion and no stitches. It is an outpatient treatment: you go home right away.

More than twenty years of history

IPL has been used in dermatology since the 1990s. In 2002, Dr Russell Toyos, in the United States, had the idea of applying it to ocular rosacea and meibomian gland dysfunction. Since then, more than twenty years of publications have expanded our knowledge [3].

I always use it as part of a comprehensive ocular surface management plan, alongside a full assessment (OSDI questionnaire, tear break-up time test, staining, meibography). IPL is not a miracle solution: it is one tool among others in the stepwise treatment of dry eye, to be introduced at the right time.

How it works

4 ways IPL acts on dry eye

IPL acts simultaneously on several mechanisms of meibomian gland dysfunction, which explains its value for evaporative dry eye and blepharitis.

01 — Thermal

Liquefying the secretions

The heat generated warms the eyelids (to around 40–45 °C / 104–113 °F), above the melting point of meibomian secretions, which are abnormally thick in MGD. They liquefy and regain their fluidity, making the manual gland expression performed afterwards easier.

02 — Vascular

Reducing abnormal blood vessels

IPL targets the small dilated blood vessels (telangiectasias) responsible for redness and rosacea. The heat partially reduces them, which helps decrease the chronic inflammation they sustain.

03 — Anti-Demodex

Reducing Demodex

Demodex mites colonize the eyelash follicles and sustain inflammation. IPL reduces their population, which lightens the overall inflammatory load on the eyelids.

04 — Anti-inflammatory

Calming inflammation

IPL helps reduce certain inflammatory mediators on the surface of the eye. This anti-inflammatory effect contributes to a lasting improvement in comfort by breaking the vicious circle of inflammation and dryness.

The treatment plan

The 4-session protocol

Why four sessions rather than just one? Because meibomian gland dysfunction is chronic: it is the gradual build-up of effects, session after session, that establishes a lasting benefit.

Session 1 · Day 0

Assessment & first session

Full ocular surface assessment (OSDI, tear break-up time test, staining, meibography), followed by a first IPL session with settings tailored to your skin, and then manual gland expression.

Session 2 · ≈ Day 15

Second session

Quick clinical check, second IPL session with the intensity adjusted to your tolerance, then gland expression. The liquefaction of secretions starts to take hold.

Session 3 · ≈ Day 30

Third session

Review of how your symptoms are progressing, third IPL session to consolidate the anti-inflammatory effect and further reduce Demodex, with gland expression.

Session 4 · ≈ Day 45

Final session & follow-up

A final session completes the protocol, followed by a post-treatment assessment. A check-up at around 3 months reviews progress, and a maintenance session 6 to 12 months later may be offered depending on how things evolve.

Key points about the schedule: each session lasts about 15 minutes and the recommended interval is about 2 weeks. You can return to your normal activities immediately. Improvement is not instant: it appears from about one month onwards, with the optimal effect usually reached around 3 months after the last session. A session-by-session breakdown is available on my IPL Treatment page.

Who is it for?

Indications & contraindications

IPL is not suitable for everyone. An in-office assessment is essential to evaluate your situation and adjust the settings safely.

Main indications
  • Moderate to severe meibomian gland dysfunction (MGD)
  • Chronic posterior blepharitis
  • Ocular rosacea (redness, telangiectasias)
  • Dry eye that does not respond to artificial tears
  • Dry eye after LASIK or PRK
  • Confirmed or suspected demodicosis
  • Chronic functional watery eyes (epiphora)
Contraindications (relative or absolute)
  • Skin phototype VI — very dark skin (risk of skin burns)
  • Recent tan (less than 2 weeks)
  • Photosensitizing medications (isotretinoin, tetracyclines)
  • Pregnancy (relative contraindication — to be discussed)
  • History of lupus, photodermatosis, porphyria
  • Suspicious pigmented lesion around the eye
  • Uncontrolled herpes in the treatment area

Good to know: skin phototypes V and VI are not absolute contraindications. Adjusting the settings (lower intensity, skin protection) may make treatment possible. A thorough consultation is needed to weigh the benefits and risks in your case.

Level of evidence

What the studies say

I want to be honest on this point: IPL has been the subject of many publications, but the level of evidence remains variable. Here is what can be said today, without overpromising.

The Cochrane review by Cote et al. (2020), as well as subsequent reviews, found low- to moderate-certainty evidence in favor of IPL for meibomian gland dysfunction, with improvements in tear break-up time and symptom scores (OSDI). The published protocols remain highly heterogeneous [1].

The study by Toyos et al. (2015) is the one that popularized IPL in ophthalmology; the first randomized controlled trial was by Craig et al. (2015), which showed a significant improvement in the tear film and symptoms compared with the control [3][4].

More recently, the literature review by Fineide et al. (2024) brought together some fifty studies: a favorable effect on MGD, a variable level of evidence, and very rare serious adverse effects [2]. In practice, I combine IPL with manual gland expression, a combination described in the literature [5].

In summary: IPL improves and relieves symptoms in many well-selected patients, but it does not cure a chronic disease. This is the spirit in which I offer it, as part of the comprehensive management recommended by professional societies [6].

Coverage

Fees & reimbursement

A common — and legitimate — question. Here is what you need to know before starting a treatment protocol.

National health insurance & mutuelles

IPL is not covered by French national health insurance (Assurance Maladie), except in very specific and rare cases. Depending on your policy, some complementary health insurers (mutuelles) offer a partial allowance: check directly with your insurer, as terms vary widely from one policy to another.

A quote before any treatment

A detailed quote is given to you at the first consultation, before the protocol begins. That way, you know exactly what to expect. Feel free to ask me any questions about costs and practical arrangements during the assessment: transparency is part of the process.

Frequently asked questions

Your questions about IPL and dry eyes

Next step

Get a clear picture of your dry eye

The only way to know whether IPL is right for you is a personalized ocular surface assessment. I see patients at the OPHTALIFE practice in Boulogne-Billancourt, next to Paris, to evaluate your eyes and recommend, with full transparency, the most appropriate treatment.

Cabinet OPHTALIFE — Boulogne-Billancourt (92)
Former assistant surgeon, Hôpital des Quinze-Vingts (Paris)
Available on Doctolib
Learn more

Related pages

Treatment
IPL treatment
The reference page: detailed protocol, what happens during a session, expected results and scientific evidence.
Read →
Condition
Dry eye disease
Diagnosis (OSDI, tear break-up time test), causes and stepwise treatment.
Read →
Condition
Blepharitis
Eyelid inflammation, meibomian gland dysfunction, Demodex, eyelid hygiene and treatments.
Read →
Blog
Am I eligible for refractive surgery?
The criteria for life without glasses — including the role of the ocular surface in the decision.
Read →
Bibliography

Scientific references

This article is based on international guidelines and key publications in ophthalmology. Sources can be verified via their DOI.

  1. 1

    Cote S, Bosc R, Mantelli F, et al. Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction. Cochrane Database Syst Rev. 2020;3(3):CD013559.

  2. 2

    Fineide F, Magnø MS, Khan AZ, et al. Intense pulsed light treatment in meibomian gland dysfunction: Past, present, and future. Acta Ophthalmol. 2024;102(4):e414-e442.

  3. 3

    Toyos R, McGill W, Briscoe D. Intense pulsed light treatment for dry eye disease due to meibomian gland dysfunction; principles and case reports. Photomed Laser Surg. 2015;33(1):41-46.

  4. 4

    Craig JP, Chen YH, Turnbull PR. Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2015;56(3):1965-1970.

  5. 5

    Vegunta S, Patel D, Shen JF. Combination therapy of intense pulsed light therapy and meibomian gland expression (IPL/MGX) can improve dry eye symptoms and meibomian gland function in patients with refractory dry eye: a retrospective analysis. Cornea. 2016;35(3):318-322.

  6. 6

    Jones L, Downie LE, Korb D, et al. TFOS DEWS II Management and Therapy Report. Ocul Surf. 2017;15(3):575-628.

  7. 7

    Hage A, Knoeri J, Leveziel L, et al. EYERUBBICS: The Eye Rubbing Cycle Study. J Clin Med. 2023;12(4):1529.

The content of this website is for information purposes only and is not a substitute for a medical consultation. Any treatment decision should be made together with your ophthalmologist.